Ubiquiti Networks (UBNT) downgraded at Pacific Crest to Sector Perform, Pacific Crest said. Sales are declining.
Ubiquiti Networks downgraded at Deutsche from Buy to Hold, Deutsche Bank said. $12 price target. Company guided lower, because of counterfeiting issues.
Ubiquiti Networks downgraded at Wedbush. Shares of UBNT downgraded to Neutral from Outperform, Wedbush said. $8 price target. Counterfeiting issue to take longer to resolve.
Verisign (VRSN) downgraded at Baird from Outperform to Neutral, Robert Baird said. Valuation call, based on a $47 price target.
STOCK COMMENTS / EPS CHANGESAlliant Techsystems (ATK) numbers boosted at Credit Suisse. Shares of ATK now seen reaching $56, according to Credit Suisse. Estimates also upped, as the company is realizing higher margins. Neutral rating. Enersys (ENS) numbers raised at Jefferies. Shares of ENS now seen reaching $43, Jefferies said. Estimates also raised on strong execution. Buy rating. ExactTarget (ET) estimates, target raised at Lazard. Shares of ET now seen reaching $32, according to Lazard. Estimates also increased, given the company's new guidance. JPMorgan (JPM) estimates cut at UBS through 2013, UBS said. Company has delayed its share buybacks. Buy rating and $46 price target. Nordstrom (JWN) estimates, target raised at Credit Suisse. Shares of JWN now seen reaching $56, according to Credit Suisse. Estimates also increased, as the company is taking market share. Neutral rating. Kohl's (KSS) numbers lowered at BMO Capital. Shares KSS now seen reaching $58, BMO Capital said. Estimates also lowered on gross margin threshold reset. Outperform rating. Medivation (MDVN) estimates, target cut at Credit Suisse. Shares of MDVN now seen reaching $120, according to Credit Suisse. Estimates also reduced, given rising operating costs. Outperform rating. Noble Energy (NBL) numbers increased at Guggenheim. NBL estimates were raised through 2013, Guggenheim said. New Falkland deal should add to earnings. Buy rating and new $120 price target. NVIDIA (NVDA) numbers raised at BMO Capital. Shares of NVDA now seen reaching $16, BMO Capital said. Estimates also raised on strong results and guide. Market Perform rating. ViroPharma (VPHM) numbers raised at Jefferies. Shares of VPHM now seen reaching $29, Jefferies said. Estimates also raised on solid 2Q12. Buy rating. >To submit a news tip, email: firstname.lastname@example.org.
Twitter and become a fan on Facebook.